EU's Breton expects J&J vaccine OK soon, not worried about overall second-quarter doses
Reuters
Published Mar 09, 2021 12:23PM ET
BRUSSELS (Reuters) - The European Union is likely to issue its approval for the anti-COVID-19 vaccine of Johnson&Johnson soon, Internal Market Commissioner Thierry Breton said, adding he was not worried reaching the overall EU goal for vaccines from all producers in the second quarter.
"I have the feeling that EMA will give its authorisation within the next hopefully days or hours, which is very good news because then we will have four vaccines ready to go," Breton told a news conference.
He said the approval for Johnson&Johnson would bring the number of vaccines available in the EU to four. This will help the EU meet its target of 300 million doses in the second quarter, even if some of the producers experience problems.
Johnson & Johnson (NYSE:JNJ) has told the European Union it was facing supply issues that may complicate plans to deliver 55 million doses of its COVID-19 vaccine to the bloc in the second quarter of the year, an EU official told Reuters.
"I learned that when you start to produce, it is a bumpy road. If I look at Johnson and Johnson I understand that they had some difficulties in the U.S., ... That they had to make an alliance with another company Merck," Breton said.
"We have our target for Q2, and we have already integrated the ups and downs. I am not worried with the internal target that we have, we know that some will do better ... and some may be a little bit late," Breton said. "So do not believe that because one company has a problem that overall it will jeopardise the whole programme," he said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.